GAMMA Investing’s Bright Minds Biosciences DRUG Stock Holding History

GAMMA Investing’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.29K	Buy	46 +26	+130%	+$1.84K	﹤0.01%	3911
2026 Q2	$1.4K	Sell	20 -13	-39%	-$1.02K	﹤0.01%	3801
2026 Q1	$2.41K	Buy	+33	New	+$2.66K	﹤0.01%	3611

Other funds holding DRUG

Rydar Equities Weatherford, Texas $194M AUM 23.21% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GAMMA Investing's DRUG Position: Q3 2026 in Review

GAMMA Investing increased its Bright Minds Biosciences (DRUG) stake by 130% in Q3 2026, buying an estimated $1.84K and bringing the position to 46 shares worth $2.29K. The position accounts for ﹤0.01% of the portfolio, ranked #3911.

GAMMA Investing first reported a position in DRUG in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.41K in Q1 2026. 6 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.

GAMMA Investing held 46 shares of Bright Minds Biosciences worth $2.29K as of Q3 2026.
GAMMA Investing bought 26 Bright Minds Biosciences shares in Q3 2026, an estimated $1.84K.
Bright Minds Biosciences made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3911 holding.
GAMMA Investing first reported a position in Bright Minds Biosciences in Q1 2026 and has held it in 3 quarters since.
GAMMA Investing's Bright Minds Biosciences position peaked at $2.41K in Q1 2026.
6 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.